SyntekaBio Inc (226330 KQ) stock market data APIs
₩4100.0287
203.32(5%)
as of October 16, 2025
Try our APIs with
free plan!
SyntekaBio Inc Financial Data Overview
Price chart is built with
Anychart
SyntekaBio, Inc. operates as an artificial intelligence new drug development company based on genomic big data primarily in South Korea. It derives new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology. The company also researches and develops biomarker detection for individual cancer drug screening, disease susceptibility, immune typing, pharmacogenomic typing, and multi-omics information-based drug side effect prediction technology. The company was founded in 2009 and is headquartered in Daejeon, South Korea.
Prev. Close
4100.0287
Open
4303.3469
High
4303.3469
Low
4016.3246
52 wk Range
3845-9430
Market Cap
62 331 M
Shares Outstanding
15 258 K
Revenue
1 328 M
EPS
-247.3495
Beta
0.576
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get SyntekaBio Inc data using free add-ons & libraries
Get SyntekaBio Inc Fundamental Data
SyntekaBio Inc Fundamental data includes:
- Net Revenue: 1 328 M
- EBITDA: -11 286 796 288
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-06-30
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
SyntekaBio Inc News
New
2023 Trends in New Drug Development
The webinar features panelists from Columbia University, Janssen, Syntekabio (KOSDAQ:226330.KQ) and Auctus Capital New York, N.Y. —News Direct— Syntekabio, Inc. Syntekabio (KOSDAQ:226330.KQ)(226...
New Cloud Platform “STB CLOUD” Disrupts AI Drug Discovery Worldwide (KOSDAQ:226330.KQ)
Powered by Syntekabio’s own MAHA supercomputing, the AI-based one-stop cloud service system STB CLOUD ensures the efficient discovery of small molecule drug candidates New York, NY —News Direct�...
A.I. in New Drug Discovery and Development Takes Center Stage at New York Health Forum (226330.KQ)
New York, NY —News Direct— Syntekabio, Inc. The 19th New York Health Forum, hosted by W Medical Strategy Group, celebrated its year end on Nov. 28 with a successful gathering of physicians, execu...
A.I. Drug Discovery Company Syntekabio (KOSDAQ:226330.KQ) to Explore Partnerships at the J.P. Morgan Healthcare Conference and Biotech Showcase™ 2023
New York, NY —News Direct— Syntekabio, Inc. Syntekabio (KOSDAQ:226330.KQ)(226330:KS), a global AI drug discovery and development company, will participate in the 41st annual J.P. Morgan Healthcar...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
